BI Asset Management Fondsmaeglerselskab A S Has $723,000 Position in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• BI Asset Management Fondsmaeglerselskab A S reduced its position in Zimmer Biomet by 32.4%, selling 3,058 shares and leaving them with 6,391 shares valued at $723,000.
• Zimmer Biomet reported earnings of $2.07 EPS for the latest quarter, exceeding expectations of $1.98 EPS, with revenues of $2.08 billion.
• The company announced a quarterly dividend of $0.24 per share, indicating an annualized dividend of $0.96 and a yield of 0.9%.

BI Asset Management Fondsmaeglerselskab A S lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 32.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,391 shares of the medical equipment provider's stock after selling 3,058 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Zimmer Biomet were worth $723,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Zimmer Biomet by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider's stock valued at $2,609,130,000 after purchasing an additional 166,763 shares during the last quarter. Northern Trust Corp lifted its position in Zimmer Biomet by 7.6% during the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock worth $250,367,000 after acquiring an additional 167,435 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after acquiring an additional 1,488,918 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Zimmer Biomet by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider's stock worth $233,009,000 after acquiring an additional 58,060 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Zimmer Biomet by 8.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,767,901 shares of the medical equipment provider's stock worth $186,743,000 after acquiring an additional 140,531 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Trading Down 0.6%

Shares of Zimmer Biomet stock traded down $0.68 during trading on Wednesday, hitting $106.86. 480,820 shares of the company were exchanged, compared to its average volume of 2,040,408. The firm has a market capitalization of $21.17 billion, a P/E ratio of 25.99, a price-to-earnings-growth ratio of 2.11 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $116.71. The firm's fifty day moving average price is $96.17 and its 200 day moving average price is $99.34. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. The business had revenue of $2.08 billion for the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet's dividend payout ratio is currently 23.36%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ZBH. Royal Bank Of Canada boosted their price objective on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. The Goldman Sachs Group dropped their price objective on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Robert W. Baird lowered their target price on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. JMP Securities lowered their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Nine analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and a consensus target price of $111.44.

Insider Activity

In other news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider owned 20,424 shares in the company, valued at $1,940,280. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.70% of the stock is currently owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.